Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 101–200 of 892
Treatment of invasive candidiasis in the elderly: a review
Dimοpoulos, G., Flevari, A., Θεοδωρακοπούλου, Μ., VELEGRAKI, & Armaganidis (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39120 · Cited by 132
Kett, D. H., Shorr, A. F., Reboli, A. C., Reisman, A. L., Biswas, P., & Schlamm, H. T. (2011) · Critical Care · doi:10.1186/cc10514 · Cited by 100
“To validate these guidelines for the treatment of candidemia, we identified a group of patients with critical illness at study entry in a prospective, randomized clinical trial that compared anidulafungin with fluconazole [23].”
BackgroundMethodResultInfluentialSelf-citationAntifungal therapy in invasive fungal infections
Chen, S. C. ‐., Playford, E. G., & Sorrell, T. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.002 · Cited by 109
“In this class, anidulafungin was demonstrably superior to fluconazole in a recent RCT [25], however it is generally accepted that the three echinocandins are of similar efficacy in IC.”
BackgroundWhen Primary Antifungal Therapy Fails
Nucci, M., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/587101 · Cited by 99
“However, even with these advances, therapy failure is still a substantial clinical problem [3], occurring in 20%-60% of patients with invasive candidiasis [4-11], in 40%-70% of patients with invasive aspergillosis (IA) [12-15], and in 30%100% of patients with invasive fusariosis [16].”
BackgroundWhat has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Cornely, O. A. (2008) · Infection · doi:10.1007/s15010-008-7357-z · Cited by 112
Sofjan, A. K., Mitchell, A., Shah, D. N., Nguyen, T., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.013 · Cited by 95
Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer
Khuri, F. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078101 · Cited by 105
Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis
Gafter‐Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., & Paul, M. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1011 · Cited by 102
Twenty-two years of candidaemia surveillance: results from a Norwegian national study
Hesstvedt, L., Gaustad, P., Andersen, C. T., Haarr, E., Hannula, R., Haukland, H. H., Hermansen, N. O., Larssen, K. W., Mylvaganam, H., Ranheim, T. E., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.008 · Cited by 101
New Perspectives on Antimicrobial Agents: Isavuconazole
Lewis, J. S., Wiederhold, N. P., Hakki, M., & Thompson, G. R. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00177-22 · Cited by 105
Reboli, A. C., Shorr, A. F., Rotstein, C., Pappas, P. G., Kett, D. H., Schlamm, H. T., Reisman, A. L., Biswas, P., & Walsh, T. J. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-261 · Cited by 94
Self-citationStrategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries
Kaur, H., & Chakrabarti, A. (2017) · Journal of Fungi · doi:10.3390/jof3030041 · Cited by 93
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 122
“The overall recommendation assigned a lower score to anidulafungin due to the low number of neutropenic patients in the clinical trial.(44) Also, liposomal formulation of amphotericin B could be used but is less recommended due to the potential toxicity.”
BackgroundResultIbrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91
Baden, L. R., Swaminathan, S., Almyroudis, N. G., Angarone, M., Baluch, A., Barros, N., Buss, B., Cohen, S. H., Cooper, B., Chiang, A. D., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0056 · Cited by 125
Schroeder, M., Weber, T., Denker, T., Winterland, S., Wichmann, D., Rohde, H., Ozga, A.-K., Fischer, M., & Kluge, S. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00755-8 · Cited by 89
Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
(2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89
Kumar, A. (2014) · Virulence · doi:10.4161/viru.26913 · Cited by 86
Antifungal stewardship in invasive Candida infections
Ruhnke, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12622 · Cited by 99
“; with double dose as ‘loading dose’ on day 1) (see Table 3) [29–33].”
BackgroundEven, C., Bastuji‐Garin, S., Hicheri, Y., Pautas, C., Botterel, F., Maury, S., Cabanne, L., Bretagne, S., & Cordonnier, C. (2010) · Haematologica · doi:10.3324/haematol.2010.030825 · Cited by 84
“43 Follow-up, months [extrems] 24 [5-104] 23 [5-112] -”
Current Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 84
“3%).(236) These findings were not significantly different from those seen with the comparator.”
MethodResultThompson, G. R., Soriano, À., Honoré, P. M., Bassetti, M., Cornely, O. A., Kollef, M. H., Kullberg, B. J., Pullman, J. R., Hites, M., Fortün, J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00551-0 · Cited by 94
“7,8 They are efficacious 18,19 and associated with high rates of treatment success, including improved survival.”
Self-citationSlenker, A. K., Keith, S. W., & Horn, D. L. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.004 · Cited by 91
“A recent study proved noninferiority of the echinocandin anidulafungin compared to fluconazole in the treatment of Candida BSI (Reboli et al., 2007).”
BackgroundAdvances in Antifungal Therapy
Sable, C. A., Strohmaier, K. M., & Chodakewitz, J. A. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.062906.071602 · Cited by 81
Invasive fungal infections in patients with cancer in the Intensive Care Unit
Sipsas, N. V., & Kontoyiannis, D. P. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.017 · Cited by 81
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80
“, 2008, 2009b) and may be superior to fluconazole as primary therapy for IC (Reboli et al., 2007).”
BackgroundChen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Candidemia and invasive candidiasis: A review of the literature for the burns surgeon
Ha, J. F., Italiano, C. M., Heath, C. H., Shih, S., Rea, S. M., & Wood, F. M. (2010) · Burns · doi:10.1016/j.burns.2010.01.005 · Cited by 97
“[99] Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al.”
Invasive Fungal Infections in the Intensive Care Unit
Ostrosky-Zeichner, L., & Al-Obaidi, M. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.005 · Cited by 76
Clinical perspectives on echinocandin resistance among Candida species
Shields, R. K., Nguyen, M. H., & Clancy, C. J. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000215 · Cited by 76
Ruhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 88
“(nongranulocytopenic) Cure Echinocandin L-AmB Azole A A C I I I (127,128,131,133,134,139-143,153,342)”
Aguado, J. M., Ruíz-Camps, I., Muñóz, P., Mensa, J., Almirante, B., Vázquez, L., Rovira, M., Martín‐Dávila, P., Moreno, A., Álvarez-Lerma, F., et al. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.01.008 · Cited by 94
Chau, M., Daveson, K., Alffenaar, J. C., Gwee, A., Ho, S. A., Marriott, D. J. E., Trubiano, J. A., Zhao, J., & Roberts, J. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15587 · Cited by 78
Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates
Cohen‐Wolkowiez, M., Benjamin, D. K., Piper, L., Cheifetz, I. M., Moran, C., Liu, P., Aram, J. A., Kashuba, A. D. M., Capparelli, E. V., Walsh, T. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.26 · Cited by 78
Self-citationEuropean expert opinion on the management of invasive candidiasis in adults
Kullberg, B. J., Verweij, P. E., Akova, M., Arendrup, M. C., Billé, J., Calandra, T., Cuenca‐Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03615.x · Cited by 78
“fluconazole has suggested the superiority of echinocandins, even in less severely ill patients [22].”
BackgroundResultInfluentialRole of isavuconazole in the treatment of invasive fungal infections
Wilson, D. T., DiMondi, V. P., Johnson, S., Jones, T. M., & Drew, R. H. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s90335 · Cited by 77
“31”
Mazi, P. B., Olsen, M. A., Stwalley, D., Rauseo, A. M., Ayres, C., Powderly, W. G., & Spec, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac004 · Cited by 68
Dickwella Widanage, M. C., Gautam, I., Sarkar, D., Mentink-Vigier, F., Vermaas, J. V., Ding, S.-Y., Lipton, A. S., Fontaine, T., Latgé, J.-P., Wang, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50799-8 · Cited by 70
Significant differences in drug susceptibility among species in the Candida parapsilosis group
Asbeck, E. C. V., Clemons, K. V., Martinez, M., Tong, A.-J., & Stevens, D. A. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.04.019 · Cited by 79
Overview of treatment options for invasive fungal infections
Pound, M. W., Townsend, M. L., Dimondi, V., Wilson, D., & Drew, R. H. (2011) · Medical Mycology · doi:10.3109/13693786.2011.560197 · Cited by 70
Zirkel, J., Klinker, H., Kuhn, A., Abele-Horn, M., Tappe, D., Turnwald, D., Einsele, H., & Heinz, W. J. (2012) · Medical Mycology · doi:10.3109/13693786.2011.587211 · Cited by 70
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
Bow, E. J., Evans, G., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R., Shafran, S. D., Sheppard, D., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 70
“Can J Infect Dis Med Microbiol Vol 21 No 4 Winter 2010 e139 the treatment of C/IC has been evaluated in large randomized clinical trials, there were too few neutropenic patients in both clinical trials (anidulafungin 2% [355] and micafungin 10% [356]) to come to any firm conclusions about their use in neutropenic pati…”
MethodSelf-citationAntifungal prophylaxis in pediatric hematology/oncology: New choices & new data
Dvorak, C. C., Fisher, B. T., Sung, L., Steinbach, W. J., Nieder, M. L., Alexander, S. W., & Zaoutis, T. E. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23415 · Cited by 71
“The echinocandins may be superior to fluconazole [48] or amphotericin B [49] for treatment of invasive candidiasis which, when combined with their anti-Aspergillus activity and excellent safety profile, makes them an attractive option for antifungal prophylaxis.”
BackgroundManagement bundles for candidaemia: the impact of compliance on clinical outcomes
Takesue, Y., Ueda, T., Mikamo, H., Oda, S., Takakura, S., Kitagawa, Y., KOHNO, S., on behalf of the ACTIONs Project, Masuda, A., Yoshida, C., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku414 · Cited by 77
Pfaller, M. A., Chaturvedi, V., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., & Ramani, R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00493-08 · Cited by 68
“These high-MIC strains are sufficiently rare that they have not been encountered with any frequency in clinical trials (15, 17, 22, 25, 26, 33), although several isolates with echinocandin MICs of 2 g/ml have recently been associated with clinical resistance to echinocandin therapy in published case reports (2, 5, 6,…”
BackgroundLamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2020) · Journal of Fungi · doi:10.3390/jof7010017 · Cited by 69
Epidemiology of invasive fungal infections in neonates and children
Steinbach, W. J. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03288.x · Cited by 76
“parapsilosis disease, but trials have shown decreased clinical efficacy as compared with infection with other Candida species [57].”
ResultSun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 74
Antifungals to treatCandida albicans
Moudgal, V. V., & Sobel, J. D. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.493875 · Cited by 85
“compared the clinical and microbiological efficacy of anidulafungin and fluconazole for the treatment of 245 patients with invasive candidiasis [93].”
ResultEchinocandin pharmacodynamics: review and clinical implications
Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 67
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Self-citationWang, J.-F., Xue, Y., Zhu, X.-B., & Fan, H. Z. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2287-4 · Cited by 72
“The serious AEs in the fluconazole arm were deep-vein thrombosis, elevated levels of hepatic enzymes, and fluconazole infusion complicated cellulitis [20, 22].”
BackgroundResultInfluentialMichallet, M., & Ito, J. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1178 · Cited by 69
Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect
Wiederhold, N. P. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1be7f · Cited by 65
Recommendations for the treatment of established fungal infections
Thursky, K., Playford, E. G., Seymour, J. F., Sorrell, T. C., Ellis, D. H., Guy, S., Gilroy, N. M., Chu, J., & Shaw, D. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01725.x · Cited by 68
Keighley, C., Cooley, L., Morris, A. J., Ritchie, D., Clark, J. E., Boan, P., & Worth, L. J. (2021) · Internal Medicine Journal · doi:10.1111/imj.15589 · Cited by 74
Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy
Vázquez‐Grande, G., & Kumar, A. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398742 · Cited by 82
Management of infected pancreatic necrosis in the intensive care unit: a narrative review
Wolbrink, D. R. J., Kolwijck, E., ten Oever, J., Horvath, K. D., Bouwense, S. A. W., & Schouten, J. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.06.017 · Cited by 70
Fungicidal versus Fungistatic: what's in a word?
Lewis, J. S., & Graybill, J. R. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.6.927 · Cited by 62
Garnacho-Montero, J., Díaz-Martín, A., Cantón-Bulnes, L., Ramírez, P., Sierra, R., Arias-Verdú, D., Rodríguez-Delgado, M., Loza-Vázquez, A., Rodriguez-Gomez, J., Gordón, M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002867 · Cited by 62
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Invasive fungal infections in transplant recipients
Vázquez, J. A., Miceli, M. H., & Alangaden, G. J. (2013) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936113491936 · Cited by 69
“…to severe infections, patients with infections due to C. glabrata and C. krusei, and those who have a history of prior azole exposure [Pappas et al. 2009; Vazquez and Sobel, 2006; Chandrasekar and Sobel, 2006; Kuse et al. 2007; Reboli et al. 2007; Cornely et al. 2007; Sobel and Revankar, 2007].”
BackgroundPetraitienė, R., Petraitis, V., Hope, W. W., Mickiene, D., Kelaher, A. M., Murray, H. A., Mya-San, C., Hughes, J. E., Cotton, M. P., Bacher, J. D., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00674-08 · Cited by 66
“Importantly, however, randomized clinical trials of echinocandins versus amphotericin or fluconazole have not shown an excess of endophthalmitis in adult patients, which may be due to some activity at relatively low drug exposures (21, 31).”
BackgroundSelf-citationFactors related to outcome of bloodstream infections due to Candida parapsilosis complex
Barchiesi, F., Orsetti, E., Osimani, P., Catassi, C., Santelli, F., & Manso, E. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1704-y · Cited by 69
Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
Liang, S. Y., & Kumar, A. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0493-6 · Cited by 76
Reemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA.
Poowanawittayakom, N., Dutta, A., Stock, S., Touray, S., Ellison, R. T., & Levitz, S. M. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.171807 · Cited by 58
Kabbara, N., Lacroix, C., Peffault de Latour, R., Socie, G., Ghannoum, M., & Ribaud, P. (2008) · Haematologica · doi:10.3324/haematol.11149 · Cited by 61
“parapsilosis.(8) Recently, Cheung et al.”
Fungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.002 · Cited by 61
Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 60
“Overall, the toxicity profile of these agents is quite favorable, with reported adverse event rates similar to that of fluconazole and lower than those of amphotericin B formulations (15, 20, 29).”
EUCAST technical note on anidulafungin
Arendrup, M. C., Rodriguez-Tudela, J.-L., Lass-Flörl, C., Cuenca-Estrella, M., Donnelly, J. P., & Hope, W. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03647.x · Cited by 60
“[4–9].”
MethodRuhnke, M., Paiva, J. A., Meersseman, W., Pachl, J., Grigoras, I., Sganga, G., Menichetti, F., Montravers, P., Auzinger, G., Dimopoulos, G., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03784.x · Cited by 58
“A similar post hoc analysis showed a 69% global success rate with anidulafungin in ICU patients at EOIVT, compared with 76% in the overall population of that study; both analyses treated missing and unknown responses as therapeutic failures [13,14] while our study excluded them from the primary endpoint.”
InfluentialTraditional and Emerging Antifungal Therapies
Arnold, T. M., Dotson, E. K., Sarosi, G. A., & Hage, C. A. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200906-048al · Cited by 69
Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit
Bassetti, M., Mikulska, M., & Viscoli, C. (2010) · Critical Care · doi:10.1186/cc9239 · Cited by 57
“Most of the patients included in studies on epidemiology or treatment of invasive candidiasis had candidemia (approximately 68 to 90%), with or without other sites aff ected, while peritonitis was the second most common disease (approximately 7 to 30% of subjects) [ 1-3 ].”
BackgroundBlyth, C. C., Hale, K. A., Palasanthiran, P., O'Brien, T. A., & Bennett, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006343.pub2 · Cited by 59
Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection
Levinson, T., Dahan, A., Novikov, A., Paran, Y., Berman, J., & Ben‐Ami, R. (2021) · Mycoses · doi:10.1111/myc.13191 · Cited by 50
Invasive fungal infections in acute and chronic liver impairment: A systematic review
Lahmer, T., Pietrobom, P. M. P., Schmid, R. M., & Colombo, A. L. (2021) · Mycoses · doi:10.1111/myc.13403 · Cited by 61
Marukutira, T., Huprikar, S. S., Azie, N. E., Quan, S.-P., Meier‐Kriesche, U., & Horn, D. (2014) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s53910 · Cited by 64
The echinocandins: three useful choices or three too many?
Bal, A. M. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.011 · Cited by 66
“In a multicentre trial on the treatment of invasive candidiasis, ANI was shown to be non-inferior to FLC [43].”
BackgroundMethodResultRare and emerging Candida species
Johnson, E. M. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0020-z · Cited by 57
“The MICs for the echinocandin group are higher for C. parapsilosis than for C. albicans [25,26], although most isolates have MIC 2 μg/mL or less, which is the proposed breakpoint for resistance [27•], and appear to respond to the echinocandins in clinical trials [28, 29 ].”
BackgroundInfluentialAttributable mortality of candidemia after introduction of echinocandins
Cornely, F. B., Cornely, O. A., Salmanton‐García, J., Koehler, F. C., Koehler, P., Seifert, H., Wingen‐Heimann, S., & Mellinghoff, S. C. (2020) · Mycoses · doi:10.1111/myc.13177 · Cited by 54
Diagnosis and Treatment of Candidemia in the Intensive Care Unit
Bassetti, M., Giacobbe, D. R., Vena, A., & Wolff, M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693704 · Cited by 72
Fungal infections in children with haematologic malignancies and stem cell transplant recipients
Otto, W. R., & Green, A. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16452 · Cited by 61
“One study comparing an echinocandin to fluconazole showed non-inferiority; however, there was a trend towards more favourable outcomes with the echinocandin (Reboli et al., 2007).”
ResultKarthaus, M. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-145 · Cited by 58
“Micafungin and anidulafungin are also approved for the treatment of invasive candidiasis with fewer data in hematological patients [46, 47, 48].”
BackgroundPharmacokinetics and Tissue Distribution of Anidulafungin in Rats
Damle, B., Stogniew, M., & Dowell, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01596-07 · Cited by 53
Vehreschild, J. J., Müller, C., Farowski, F., Vehreschild, M. J. G. T., Cornely, O. A., Fuhr, U., Kreuzer, K., Hallek, M. J., & Kohl, V. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1212-y · Cited by 53
Invasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 63
Hall, R. G., Swancutt, M. A., Meek, C. C., Leff, R. D., & Gumbo, T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01490-12 · Cited by 57
“There is now clear evidence of the superiority of echinocandins over azoles and polyenes for the treatment of candidemia, when both success rates and mortality are considered (1, 2).”
BackgroundRosa, F. G. D., Corcione, S., Filippini, C., Raviolo, S., Fossati, L., Montrucchio, C., Aldieri, C., Petrolo, A., Cavallo, R., & Perri, G. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125149 · Cited by 56
“parapsilosis BSI with caspofungin [20], whereas a numerically lower eradication rate was found by Reboli et al with anidulafungin [21].”
Al‐Hasan, M. N., & Winders, H. R. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.05.012 · Cited by 56
Efficacy and mechanism of actions of natural antimicrobial drugs
Ye, L., Zhang, J., Xiao, W. L., & Liu, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107671 · Cited by 56
Current therapeutic approaches to fungal infections in immunocompromised hematological patients
Pagano, L., Caira, M., Valentini, C. G., Posteraro, B., & Fianchi, L. (2010) · Blood Reviews · doi:10.1016/j.blre.2009.11.003 · Cited by 54
Wiederhold, N. P., Grabinski, J. L., Garcia-Effron, G., Perlin, D. S., & Lee, S. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00959-08 · Cited by 52
“Each clinically available member of the echinocandin class of antifungals (anidulafungin, caspofungin, and micafungin) has been shown to be effective in the treatment of invasive candidiasis, with an excellent safety and drug-drug interaction profile (10, 13, 17, 21).”
BackgroundLestner, J. M., Smith, P. B., Cohen‐Wolkowiez, M., Benjamin, D. K., & Hope, W. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12025 · Cited by 50
“Candida parapsilosis and treated with an echinocandin are comparable (numerically fewer, 20 but not statistically inferior) to other antifungal agents [84].”
Backgroundthe study group Candida albicans Germ Tube Antibody Detection in Critically Ill Patients (CAGTAUCI), Pemán, J., Zaragoza, R., Quindós, G., Alkorta, M., Cuétara, M. S., Camarena, J. J., Ramírez, P., Giménez, M. J., Martín‐Mazuelos, E., et al. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-60 · Cited by 55
“Although the past few years have brought exciting developments in antifungal pharmacotherapy, the mortality rate remains excessively high [3-7].”
BackgroundFluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study
Eschenauer, G. A., Carver, P. L., Lin, S.-W., Klinker, K. P., Chen, Y.-C., Potoski, B. A., Shields, R. K., Clancy, C. J., Nguyen, M.-H., & Lam, S. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks482 · Cited by 50
New developments and directions in the clinical application of the echinocandins
Chang, C. C., Slavin, M. A., & Chen, S. C. A. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1916-3 · Cited by 56
Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance
Kotey, F. C. N., Dayie, N. T. K. D., Tetteh‐Quarcoo, P. B., & Donkor, E. S. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211026927 · Cited by 77
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.